Ocrevus Patient Assistance: an application guide for practices

What is specific about the Ocrevus application

Ocrevus is infused roughly every six months, and that long interval is the source of its particular risk: an application that stalls has a quiet failure window of months before anyone notices, and by the time the gap surfaces the next infusion may already be booked. The enrollment is effectively a hard scheduling deadline rather than a soft one, because the infusion suite reserves the chair and the drug in advance.

The patient population adds a second, easily-missed friction. Many patients with multiple sclerosis have mobility or dexterity limitations that make a printed form genuinely difficult, and a form mailed to the house is often simply never returned, which reads in the chart as a non-responsive patient rather than as an inaccessible process. The way to run an Ocrevus application is to work backwards from the scheduled infusion rather than forward from the calendar, and to keep the patient’s part to something they can complete on a phone (a signature request that needs no account at all), so the barrier is a text message, not a trip to a printer and a scanner.

Eligibility factors to verify

Genentech sets the eligibility criteria for the Ocrevus program and changes them, so the categories below are only the ones programs of this kind generally assess.They are not the criteria for this program, confirm current requirements onGenentech’s official program pagebefore telling a patient anything. We do not publish income thresholds for Ocrevus here, because a stale number on a marketing page is how a practice ends up telling a patient the wrong thing.

• Insurance status, generally aimed at patients who are uninsured, or insured but unable to access the medication through their coverage.
• Household income against the program’s own published threshold, evidenced by documentation rather than attestation.
• Residency and prescriber licensure requirements set by the program.
• A prescription written for an indication the program covers, certified by the prescribing clinician.

What the application needs

A complete Ocrevus application is assembled from the four parts below, and because Ocrevus is infused in the practice or infusion suite, the part most likely to hold it up is the one this practice controls least. Missing any one of them is what sends a form back rather than forward.

Where practices get stuck

Common workflow challenges for Ocrevus:

• Infusions are roughly six months apart, so an application that stalls has a long, quiet failure window before anyone notices.
• The infusion appointment is booked well in advance, which turns the enrollment into a hard scheduling deadline rather than a soft one.
• Patients with mobility or dexterity limitations find paper forms genuinely difficult, and a mailed form is often simply not returned.

How long an application takes

We do not publish a turnaround figure for Ocrevus, because Genentech sets it and it moves. What a practice can control is the work before submission. Four factors commonly affect the timeline: how long the patient section takes to return, how many review cycles occur between staff and the prescriber, whether the submission is complete on the first attempt, and the manufacturer review time, which we do not estimate.

How AlgoMeds handles it for Ocrevus

AlgoMeds opens the correct current Ocrevus form, including variant forms that depend on indication, already filled from the patient chart, prescriber profile, insurance on file and prior submitted applications. The patient signs from a single-use, identity-verified link sent by text message, with no account required. This can reduce printing and scanning. Required documents are checked before submission, the application is tracked to a decision, and renewals open ahead of expiry using information from the prior application.

For Ocrevus, as for every program, AlgoMeds does not determine eligibility, predict approval, or claim to improve the odds of a decision going a particular way. It removes the paperwork between a clinical decision and a submittedOcrevus application, nothing more, and nothing that touches the manufacturer’s judgement.See the full coordinator workflow.